CJC-1295
Long-acting GHRH analog with published human PK data, often stacked with ipamorelin.
Evidence Score
Score Breakdown
Want Molecular Data on Your CJC-1295 Response?
Join early access for mRNA-based monitoring — starting with GLP-1, live now.
Overview
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) with a modified amino acid sequence for extended half-life. The DAC (Drug Affinity Complex) variant binds albumin, extending its half-life to about 6–8 days. It is commonly used in anti-aging and performance protocols, often stacked with ipamorelin.
Mechanism of Action
CJC-1295 binds the GHRH receptor on pituitary somatotrophs, stimulating GH synthesis and secretion. The DAC modification creates a sustained-release effect via albumin binding. When combined with a GHRP like ipamorelin, the synergistic effect on GH release is amplified (GHRH + GHRP synergy).
Evidence Base
A published randomized, placebo-controlled study in healthy adults showed GH elevation for 6 or more days and IGF-1 elevation for 9–11 days after a single injection (ConjuChem Biotechnologies). ConjuChem's Phase II trial in HIV-associated lipodystrophy was halted in 2006 after a participant's death; a link to the drug was not established. No FDA approval.
Gene Pathway Detail
GHRH receptor activation drives GH gene (GH1) transcription in somatotrophs and downstream hepatic IGF-1 expression. The sustained GH elevation from CJC-1295 DAC produces more prolonged IGF-1 axis activation compared to pulsatile secretagogues. In blood, response duration is tracked through serum IGF-1.
mRNA Monitoring Insight
Like ipamorelin, the GH axis is best tracked through serum IGF-1; a whole-blood transcriptomic readout is not established. The sustained nature of CJC-1295 DAC may produce more detectable and consistent mRNA changes compared to short-acting secretagogues, making it potentially more amenable to transcriptomic monitoring.
Safety Considerations
Published human PK data provides some safety confidence. Development in HIV lipodystrophy was halted in 2006 after a trial participant's death. DAC variant creates sustained GH elevation that cannot be "turned off" once injected. Long-term safety of chronic GH axis stimulation is a concern. Not FDA-approved.
FAQ
What is the DAC in CJC-1295 DAC?
Quick Facts
- Category
- Growth Hormone Secretagogue
- Score
- 51/100 (C)
- Gene Pathways
- 4 characterized
Monitor Your Peptide Response
Biomeme's transcriptomic platform tracks molecular pathway engagement. GLP-1 response testing is live now — CJC-1295 monitoring is coming soon.